Additional file 1 of Intravenous vitamin C monotherapy in critically ill patients: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
Creators: name: Lee, Zheng-Yii
name: Ortiz-Reyes, Luis
name: Lew, Charles Chin Han
name: Hasan, M. Shahnaz
name: Ke, Lu
name: Patel, Jayshil J.
name: Stoppe, Christian
name: Heyland, Daren K.
Publisher: name: figshare
Year: 2024
Subjects: Medicine
Cancer
Science Policy

description: Additional file 1: Methodology. PRISMA 2020 checklist. Results. Table S1 Search strategy. Table S2 List of excluded studies. Table S3 Critical care nutrition methodological system. Table S4 Intervention. Table S5 Outcomes summary. Table S6 Summary of adverse events. Table S7 Trial sequential analysis for overall mortality (sensitivity analysis). Table S8 Differences between protocol and review. Figure S1 PRISMA flowchart. Figure S2 Risk of bias 2 traffic light plot. Figure S3 Overall mortality (single vs multicenter trials). Figure S4 Overall mortality (sepsis vs non-sepsis). Figure S5 Overall mortality (higher ≥10000 mg/day vs lower dose). Figure S6 Overall mortality (median control group mortality &gt; vs ≤ 37.5%). Figure S7 Overall mortality (median CCN score &gt;9 vs ≤9). Figure S8 Overall mortality (low vs other risk of bias). Figure S9 Overall mortality (start of intervention ≤ vs &gt;24 h of ICU admission/septic shock/pressor initiation etc.). Figure S10 Overall mortality (duration of treatment &gt; vs ≤4 days). Figure S11 Overall mortality (bolus vs continuous infusion). Figure S12 Overall mortality sensitivity analysis studies that measured and reported baseline vitamin C deficit. Figure S13 28-day mortality (single vs multicenter). Figure S14 28-day mortality (sepsis vs non-sepsis). Figure S15 28-day mortality (higher dose ≥10000 mg/day vs lower dose). Figure S16 28-day mortality (median control group mortality &gt; vs ≤ 37.5%). Figure S17 28-day mortality (median CCN score &gt;9 vs ≤9). Figure S18 28-day mortality (low vs other risk of bias). Figure S19 28-day mortality (start of intervention ≤ vs &gt;24h of ICU admission/septic shock/pressor initiation etc.). Figure S20 28-day mortality (Duration of treatment &gt; vs ≤4 days). Figure S21 28-day mortality (bolus vs continuous infusion). Figure S22 Summary of subgroup analysis for 28-day mortality. Figure S23 Longer term mortality (≥60 days). Figure S24 Duration of mechanical ventilation. Figure S25 ICU length of stay. Figure S26 Hospital length of stay. Figure S27 Incidence of acute kidney injury. Figure S28 Incidence of renal replacement therapy. Figure S29 Sequential organ failure assessment (SOFA) score at 96h. Figure S30 Dose of vasopressors. Figure S31 Days on vasopressors. Figure S32 (a) Adverse events. (b) Adverse events (with continuity correction by adding 0.01 to cells with zero events). Figure S33 Funnel plot for overall mortality. Figure S34 TSA for overall mortality—subgroup analysis in trials with below median control group mortality—relative risk reduction 30%. Figure S35 TSA for overall mortality—subgroup analysis in trials below median control group mortality—relative risk reduction 25%. Figure S36 TSA for overall mortality—subgroup analysis in trials below median control group mortality (≤37.5%)—Relative risk reduction 20%. Figure S37 TSA for overall mortality—subgroup analysis in trials above (&gt;37.5%) median control group mortality—relative risk reduction 30%. Figure S38 TSA for overall mortality—subgroup analysis in trials above (&gt;37.5%) median control group mortality—relative risk reduction 25%. Figure S39 TSA for overall mortality—subgroup analysis in trials above (&gt;37.5%) median control group mortality—relative risk reduction 20%.